biblioteca virtual en salud

Búsqueda | Gripe por A(H1N1)

  • BIREME | OPAS | OMS logo
 

Historico de búsqueda  ()

Su selección  ()

 0 documento(s) seleccionado(s).

Enviar por email

Ud. tiene 0 documento(s) seleccionado(s).

Ningún documento seleccionado

 
Resultados  1-12 de 248
1.

Inhalable Dry Powder Formulations of siRNA and pH-Responsive Peptides with Antiviral Activity Against H1N1 Influenza Virus.

Autor(es): Liang W; Chow MY; Lau PN; Zhou QT; Kwok PC; Leung GP; Mason AJ; Chan HK; Poon LL; Lam JK
Fuente: Mol Pharm;12(3): 910-21, 2015 Mar 2.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25599953
Resumen: Pulmonary delivery of siRNA has considerable therapeutic potential for treating viral respiratory infectious diseases including influenza. By introducing siRNA that targets the conserved region of viral genes encoding nucleocapsid protein (NP), viral mRNAs can be degraded and viral replication can be inhibited in mammalian cells. To enable siRNA to be used as an antiviral agent, the nucleic acid delivery barrier must be overcome. Effective local delivery of siRNA to lung tissues is required (mas)
2.

A novel video tracking method to evaluate the effect of influenza infection and antiviral treatment on ferret activity.

Autor(es): Oh DY; Barr IG; Hurt AC
Fuente: PLoS One;10(3): e0118780, 2015.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25738900
Resumen: Ferrets are the preferred animal model to assess influenza virus infection, virulence and transmission as they display similar clinical symptoms and pathogenesis to those of humans. Measures of disease severity in the ferret include weight loss, temperature rise, sneezing, viral shedding and reduced activity. To date, the only available method for activity measurement has been the assignment of an arbitrary score by a 'blind' observer based on pre-defined responsiveness scale. This manual s (mas)
3.

In vitro Antiviral Effects and 3D QSAR Study of Resveratrol Derivatives as Potent Inhibitors of Influenza H1N1 Neuraminidase.

Autor(es): Li C; Fang JS; Lian WW; Pang XC; Liu AL; Du GH
Fuente: Chem Biol Drug Des;85(4): 427-38, 2015 Apr.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25185493
Resumen: The anti-influenza virus activities of 50 resveratrol (RV: 3, 5, 4'-trihydroxy-trans-stilbene) derivatives were evaluated using a neuraminidase (NA) activity assay. The results showed that 35 compounds exerted an inhibitory effect on the NA activity of the influenza virus strain A/PR/8/34 (H1N1) with 50% inhibitory concentration (IC50 ) values ranging from 3.56 to 186.1 µm. Next, the 35 RV derivatives were used to develop 3D quantitative structure-activity relationship (3D QSAR) models fo (mas)
4.

The Nucleoprotein of Newly Emerged H7N9 Influenza A Virus Harbors a Unique Motif Conferring Resistance to Antiviral Human MxA.

Autor(es): Riegger D; Hai R; Dornfeld D; Mänz B; Leyva-Grado V; Sánchez-Aparicio MT; Albrecht RA; Palese P; Haller O; Schwemmle M; García-Sastre A; Kochs G; Schmolke M
Fuente: J Virol;89(4): 2241-52, 2015 Feb 15.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25505067
Resumen: UNLABELLED: Interferon-induced Mx proteins show strong antiviral activity against influenza A viruses (IAVs). We recently demonstrated that the viral nucleoprotein (NP) determines resistance of seasonal and pandemic human influenza viruses to Mx, while avian isolates retain Mx sensitivity. We identified a surface-exposed cluster of amino acids in NP of pandemic A/BM/1/1918 (H1N1), comprising isoleucine-100, proline-283, and tyrosine-313, that is essential for reduced Mx sensitivity in cell (mas)
5.

Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.

Autor(es): Correia V; Santos LA; Gíria M; Almeida-Santos MM; Rebelo-de-Andrade H
Fuente: J Med Virol;87(1): 45-56, 2015 Jan.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25042157
Resumen: Neuraminidase inhibitors (NAIs) oseltamivir and zanamivir are currently the only effective antiviral drugs available worldwide for the management of influenza. The potential development of resistance is continually threatening their use, rationalizing and highlighting the need for a close and sustained evaluation of virus susceptibility. This study aimed to analyze and characterize the phenotypic and genotypic NAIs susceptibility profiles of A(H1N1)pdm09 viruses circulating in Portugal from (mas)
6.

Strain-specific antiviral activity of iminosugars against human influenza A viruses.

Autor(es): Hussain S; Miller JL; Harvey DJ; Gu Y; Rosenthal PB; Zitzmann N; McCauley JW
Fuente: J Antimicrob Chemother;70(1): 136-52, 2015 Jan.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25223974
Resumen: OBJECTIVES: Drugs that target host cell processes can be employed to complement drugs that specifically target viruses, and iminosugar compounds that inhibit host α-glucosidases have been reported to show antiviral activity against multiple viruses. Here the effect and mechanism of two iminosugar α-glucosidase inhibitors, N-butyl-deoxynojirimycin (NB-DNJ) and N-nonyl-deoxynojirimycin (NN-DNJ), on human influenza A viruses was examined. METHODS: The viruses examined were a recently cir (mas)
7.

Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.

Autor(es): Matusevich OV; Egorov VV; Gluzdikov IA; Titov MI; Zarubaev VV; Shtro AA; Slita AV; Dukov MI; Shurygina AP; Smirnova TD; Kudryavtsev IV; Vasin AV; Kiselev OI
Fuente: Antiviral Res;113: 4-10, 2015 Jan.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25446335
Resumen: This study is devoted to the antiviral activity of peptide fragments from the PB1 protein - a component of the influenza A RNA polymerase. The antiviral activity of the peptides synthesized was studied in MDCK cell cultures against the pandemic influenza strain A/California/07/2009 (H1N1) pdm09. We found that peptide fragments 6-13, 6-14, 26-30, 395-400, and 531-540 of the PB1 protein were capable of suppressing viral replication in cell culture. Terminal modifications i.e. N-acetylation an (mas)
8.

[The 2013-2014 epidemic season. Hospital monitoring and antiviral therapy for influenza ].

Autor(es): Kolobukhina LV; Burtseva EI; Shelkanov MIu; Al'khovskii SV; Prilipov AG; Merkulova LN; Kisteneva LB; Vartanian RV; Kruzhkova IS; Trushakova SV; Krasnoslobodtsev KG; Avdeev SM; Sutochnikova OA; Bazarova MV; Kelly EI; Ambrosi OE; Malyshev nA; L'vov DK; Chuchalin AG
Fuente: Ter Arkh;86(10): 52-9, 2014.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25509893
Resumen: AIM: To characterize the 2013-2014 epidemic season from the results of detection of influenza infection in patients; to provide the molecular genetic characteristics of the strains isolated from deceased patients. SUBJECTS AND METHODS: The investigators examined 1203 patients (387 children, 509 people older than 16 years of age, 307 pregnant women) admitted to Moscow Clinical Infectious Diseases Hospital One with the clinical signs of acute respiratory viral diseases. Nasal lavage and autop (mas)
9.

Antiviral combinations for severe influenza.

Autor(es): Dunning J; Baillie JK; Cao B; Hayden FG
Fuente: Lancet Infect Dis;14(12): 1259-70, 2014 Dec.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25213733
Resumen: Observational data suggest that the treatment of influenza infection with neuraminidase inhibitors decreases progression to more severe illness, especially when treatment is started soon after symptom onset. However, even early treatment might fail to prevent complications in some patients, particularly those infected with novel viruses such as the 2009 pandemic influenza A H1N1, avian influenza A H5N1 virus subtype, or the avian influenza A H7N9 virus subtype. Furthermore, treatment with o (mas)
10.

Cigarette smoke attenuates the RIG-I-initiated innate antiviral response to influenza infection in two murine models.

Autor(es): Wu W; Zhang W; More S; Booth JL; Duggan ES; Liu L; Zhao YD; Metcalf JP
Fuente: Am J Physiol Lung Cell Mol Physiol;307(11): L848-58, 2014 Dec 1.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25260755
Resumen: Cigarette smoke (CS) exposure increases the frequency and severity of respiratory tract infections. Despite this association, the mechanisms underlying the increased susceptibility to respiratory virus infection are poorly understood. Retinoic acid-inducible gene I (RIG-I) is an important regulator of influenza virus-induced expression of antiviral cytokines, mainly interferons (IFNs), which are necessary to clear viral infections. In this study, we compared the innate cytokine responses of (mas)
11.

Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase.

Autor(es): Ding Y; Dou J; Teng Z; Yu J; Wang T; Lu N; Wang H; Zhou C
Fuente: Arch Virol;159(12): 3269-78, 2014 Dec.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25078390
Resumen: Scutellaria baicalensis Georgi, a Chinese herbal decoction, has been used for the treatment of the common cold, fever and influenza virus infections. In previous studies, we found that oral administration of baicalein resulted in the inhibition of influenza A virus replication in vivo, which was linked to baicalin in serum. However, the effective dose and underlying mechanisms of the efficacy of baicalin against influenza A virus have not been fully elucidated. In this study, the antiviral (mas)
12.

Antiviral drug profile of human influenza A & B viruses circulating in India: 2004-2011.

Autor(es): Potdar VA; Dakhave MR; Kulkarni PB; Tikhe SA; Broor S; Gunashekaran P; Chawla-Sarkar M; Abraham A; Bishwas D; Patil KN; Kadam AA; Kode SS; Mishra AC; Chadha MS
Fuente: Indian J Med Res;140(2): 244-51, 2014 Aug.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25297358
Resumen: BACKGROUND & OBJECTIVES: Recent influenza antiviral resistance studies in South East Asia, Europe and the United States reveal adamantane and neuraminidase inhibitor (NAIs) resistance. This study was undertaken to evaluate antiviral resistance in influenza viruses isolated from various parts of India, during 2004 to 2011. METHODS: Influenza viruses were analyzed genetically for known resistance markers by M2 and NA gene sequencing. Influenza A/H1N1 (n=206), A/H3N2 (n=371) viruses for amanta (mas)
Resultados  1-12 de 248